MASAC Document #153

MASAC Recommendation Concerning Reimbursement for Recombinant Clotting Factor Concentrates

The following document was approved by the Medical and Scientific Advisory Council (MASAC) of the National Hemophilia Foundation on November 8, 2003, and adopted by the NHF Board of Directors on November 9, 2003.

View Printer-Friendly PDF Version >>

There are now available several different recombinant factor products for the treatment of hemophilia. There are specific considerations in prescribing a product for any individual patient.

Therefore MASAC recommends that insurance companies and other third-party payers such as Medicaid, Medicare, CMS, etc. cover whichever recombinant factor product is prescribed by the patient’s treating physician.